Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
about
Astatine-211: production and availabilityImaging and drug delivery using theranostic nanoparticlesAstatine Radiopharmaceuticals: Prospects and ProblemsPreparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.An overview of targeted alpha therapy.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Radioimmunotherapy with α-particle-emitting radionuclides.Towards translation of 212Pb as a clinical therapeutic; getting the lead in!Cancer radioimmunotherapy.The role of gap junction communication and oxidative stress in the propagation of toxic effects among high-dose α-particle-irradiated human cells.Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after AdministrationMolecular targeted α-particle therapy for oncologic applications.Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure.Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles.Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapyAnti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.LET-dependent bystander effects caused by irradiation of human prostate carcinoma cells with X rays or alpha particles.A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry.Search of ligands suitable for (212)Pb/(212)Bi in vivo generators.Effect of densely ionizing radiation on cardiomyocyte differentiation from human-induced pluripotent stem cells.Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities.
P2860
Q27015038-6349AFC3-98D8-43A3-94F0-A1095F5885D1Q30449480-E9A24BF6-4898-4C55-994E-59B84C304E21Q33640550-A3A478AE-AE0A-4062-851A-496999ED9320Q33657227-F710E32F-AAE8-4575-BE32-7E85E0017732Q33746975-8D9805E4-718C-47B8-907B-F9AD484F895FQ34238513-5DD6EB04-A6E1-400F-A663-2B626DACE4E4Q34253705-94E5D26B-070C-478D-878D-3B687BD7DA32Q34419562-D31885D9-01AD-4128-99CD-D834FA599485Q35028126-4EC18BB7-9EC5-4F46-9DDD-797C56D22CBDQ35070045-ACAF909F-ED20-4D19-9A4A-B476FB68C573Q35113358-4C251D7C-C9D3-4CF0-9A69-BAF4C8FD46ABQ35287836-F7C88884-0049-4464-B96B-21DB5860C7F9Q35582104-5AA7F22A-E1AB-4E4D-955C-68624E0C30D1Q35692449-E39054C1-98D8-4758-88FA-472FE60495A2Q35814989-FA81BDC6-E818-4407-9406-62E66E70E86AQ36192306-811F2B7C-3640-49BB-80A1-82C42AFA3B33Q36372946-1CF59BDD-32ED-4C4F-B28E-B65CEB25AE14Q36534262-EC6823AA-4D87-49EE-8319-96BC292D8BB9Q36814661-6778FD67-FCF9-4166-A893-44A7C4E92F48Q37133715-A6F656D2-669B-4D36-B0C6-E3E1881B9197Q39284797-1C78C008-0818-487A-ACBB-F48BE869621DQ39913677-33B79338-8FFF-4995-9B36-9265C39D23F6Q40254341-12FD2FFE-05D6-467E-A379-5EA807831910Q40679548-C2C6C1D1-B8F6-4A51-933B-B590974EE23EQ41385806-58BCC8E2-3659-4E87-9518-C707575067FFQ41865540-7D3B1CEF-5426-4725-9020-57FF04A03CE5Q43146282-EFF1BDD4-866E-4D02-BE46-ABD8BE4BBC7BQ47106924-D4EB2783-A28C-4B20-8F11-C763EEF3AD29
P2860
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@ast
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@en
type
label
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@ast
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@en
prefLabel
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@ast
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@en
P2093
P2860
P1476
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
@en
P2093
Ganesan Vaidyanathan
Michael R Zalutsky
Oscar R Pozzi
P2860
P304
P356
10.1016/J.NUCMEDBIO.2007.03.007
P577
2007-05-11T00:00:00Z